SFM
Sphera Funds Management Portfolio holdings
AUM
$382M
This Quarter Return
+10.94%
1 Year Return
+0.41%
3 Year Return
+99.29%
5 Year Return
+177.09%
10 Year Return
+575.73%
AUM
$382M
AUM Growth
+$382M
(-5.7%)
Cap. Flow
-$40.1M
Cap. Flow
% of AUM
-10.48%
Top 10 Holdings %
Top 10 Hldgs %
34.79%
Holding
131
New
16
Increased
23
Reduced
53
Closed
27
Top Buys
| 1 |
Tower Semiconductor
TSEM
|
$8.81M |
| 2 |
Biogen
BIIB
|
$7.54M |
| 3 |
Forte Biosciences
FBRX
|
$6.4M |
| 4 |
Cytokinetics
CYTK
|
$6.01M |
| 5 |
Cidara Therapeutics
CDTX
|
$5.89M |
Top Sells
| 1 |
BridgeBio Pharma
BBIO
|
$12.1M |
| 2 |
Ultragenyx Pharmaceutical
RARE
|
$6.08M |
| 3 |
Nice
NICE
|
$5.13M |
| 4 |
Merus
MRUS
|
$4.48M |
| 5 |
Sanofi
SNY
|
$4.11M |
Sector Composition
| 1 | Healthcare | 73.22% |
| 2 | Technology | 19.05% |
| 3 | Consumer Discretionary | 1.86% |
| 4 | Utilities | 1.71% |
| 5 | Communication Services | 1.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Teva Pharmaceuticals
TEVA
$21.1B
| $27.2M | 6.38% | 1,620,990 +48,809 | +3% | +$818K |
|
2
Nova
NVMI
$7.74B
| $20.9M | 4.9% | 75,836 -14,861 | -16% | -$4.09M |
|
3
Syndax Pharmaceuticals
SNDX
$1.41B
| $14.7M | 3.45% | 1,571,564 -92,410 | -6% | -$865K |
|
|
4
Tower Semiconductor
TSEM
$6.58B
| $11.5M | 2.69% | 264,722 +203,173 | +330% | +$8.81M |
|
|
5
Cytokinetics
CYTK
$4.23B
| $10.8M | 2.53% | 326,718 +181,757 | +125% | +$6.01M |
|
|
6
Sanofi
SNY
$121B
| $10.6M | 2.49% | 219,515 -85,000 | -28% | -$4.11M |
|
|
7
Biogen
BIIB
$19.4B
| $10.4M | 2.44% | 82,738 +60,000 | +264% | +$7.54M |
|
8
AstraZeneca
AZN
$248B
| $9.44M | 2.21% | 135,060 -40,000 | -23% | -$2.8M |
|
9
Eli Lilly
LLY
$657B
| $9M | 2.11% | 11,540 -150 | -1% | -$117K |
|
10
NVIDIA
NVDA
$4.24T
| $8.61M | 2.02% | 54,515 +24,910 | +84% | +$3.94M |
|
11
Celldex Therapeutics
CLDX
$1.47B
| $8.54M | 2% | 419,540 -88,289 | -17% | -$1.8M |
|
12
Novo Nordisk
NVO
$251B
| $7.29M | 1.71% | 105,677 -12,403 | -11% | -$856K |
|
13
Amazon
AMZN
$2.44T
| $7.12M | 1.67% | 32,441 -4,166 | -11% | -$914K |
|
|
14
Cidara Therapeutics
CDTX
$1.66B
| $6.72M | 1.58% | 138,001 +120,873 | +706% | +$5.89M |
|
15
Ormat Technologies
ORA
$5.56B
| $6.53M | 1.53% | 78,000 -6,000 | -7% | -$503K |
|
16
Mineralys Therapeutics
MLYS
$1.03B
| $6.51M | 1.53% | 480,974 +15,448 | +3% | +$209K |
|
|
17
Forte Biosciences
FBRX
$137M
| $6.4M | 1.5% | +495,109 | New | +$6.4M |
|
18
Meta Platforms (Facebook)
META
$1.86T
| $6.29M | 1.48% | 8,526 -1,436 | -14% | -$1.06M |
|
19
Johnson & Johnson
JNJ
$427B
| $6.24M | 1.46% | 40,831 -12,000 | -23% | -$1.83M |
|
20
Microsoft
MSFT
$3.77T
| $5.87M | 1.38% | 11,792 +7,200 | +157% | +$3.58M |
|
21
Amicus Therapeutics
FOLD
$2.34B
| $5.68M | 1.33% | +990,718 | New | +$5.68M |
|
22
Pharvaris
PHVS
$1.39B
| $5.45M | 1.28% | 309,931 -73,925 | -19% | -$1.3M |
|
23
Eledon Pharmaceuticals
ELDN
$155M
| $5.31M | 1.25% | 1,959,610 -347,509 | -15% | -$942K |
|
24
Travere Therapeutics
TVTX
$1.56B
| $4.96M | 1.16% | 335,333 +135,333 | +68% | +$2M |
|
25
AbbVie
ABBV
$372B
| $4.69M | 1.1% | 25,256 -5,000 | -17% | -$928K |
|